OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 78. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Vaccine exposes tumours to immune cell attack	1554
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	943
A specific biomarker for insoluble tau	711
Targeting tumour-associated bacteria	709
Neutralizing Zika virus	615
A new path to targeted protein degradation?	615
The improving benefit–risk balance of phase I cancer trials	547
FDA approves a c-MET-targeted ADC for lung cancer	513
Tumour cells get a dendritic cell makeover	441
Glucose-sensitive insulin protects against hypoglycaemia	425
Promoting tissue repair after heart attack	423
Hypoimmune iPSCs escape immune detection	397
Lipid nanoparticle ferries therapeutic mRNA to the placenta	387
FDA new drug approvals in Q1 2023	384
Apolipoprotein L2 inhibitor mitigates fibrosis	379
AI serves up target and inhibitor for lung fibrosis	376
Chemical engineering of CRISPR–Cas systems for therapeutic application	373
New antibiotic for urinary tract infections nabs FDA approval	371
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	364
Target identification and assessment in the era of AI	335
mRNA vaccines for infectious diseases — advances, challenges and opportunities	313
Anti-tau antibody stumbles in phase II Alzheimer trial	306
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	294
Targeting the Hippo pathway in cancer	288
Small-molecule discovery through DNA-encoded libraries	286

FDA approves second TTR stabilizer for cardiac amyloidosis	265
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	253
Targeting drug-resistant glioblastoma	252
Degrading cell-free DNA to prevent recurrent stroke	251
2022 FDA approvals	230
Increasing the potency of T cell therapies	225
Small molecule improves muscle function in myasthenia gravis	219
Pushing both sides of the drug pricing aisle	214
Host-directed antiviral blocks SARS-CoV-2 entry	211
TCR-engineered T cells get personal	198
2025’s FDA approvals by regulatory designations	196
Inhibiting ASGR1 boosts cholesterol removal	195
FDA new drug approvals in Q2 2023	191
Rewired proteostasis in KRAS inhibitor resistance	188
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	179
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	177
An allosteric site on cereblon	175
A renaissance in targeting the PI3K/AKT/mTOR pathway	174
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	157
Mimicking the health benefits of exercise	156
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	149
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	146
R&D re-balancing act	145
The significance of blockbusters in the pharmaceutical industry	139
Base editors hit the clinic	138
Phenotypic drug discovery: recent successes, lessons learned and new directions	138
Combating antimicrobial resistance in malaria, HIV and tuberculosis	136
Roads and detours for CAR T cell therapy in autoimmune diseases	134
Amylin takes another shot at the obesity prize	133
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	126
The antibody–drug conjugate landscape	124
Antibody–drug conjugates come of age in oncology	122
Multi-TACs target solid tumours	120
Immunology on the brain	118
Gut metabolite mediates nerve repair	116
Agonist antibody lowers blood pressure	113
Reducing IL-2 toxicity	113
Monkeypox mRNA vaccine protects mice and macaques	112
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	107
Neglected tropical diseases go global	107
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	104
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	102
Designing G-protein-selective allosteric modulators	100
Targeting the ECM in melanoma	98
Redirecting mast cells for antigen-specific cancer immunotherapy	97
LRRK2-targeted Parkinson disease drug advances into phase III	96
Ribosome inhibitor combats bacterial drug resistance	95
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	94
Anti-IL-11 antibody shows anti-ageing properties	88
The European Innovation Network as a hub for medicines innovation in Europe	87

Frameworks for transformational breakthroughs in RNA-based medicines	86
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	84
Avidity in antibody effector functions and biotherapeutic drug design	78
Engineered parasite delivers proteins to the brain	78